Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

A dual-targeting, apoptosis-inducing organometallic half-sandwich iridium anticancer complex.

Novohradsky V, Zerzankova L, Stepankova J, Kisova A, Kostrhunova H, Liu Z, Sadler PJ, Kasparkova J, Brabec V.

Metallomics. 2014 Aug;6(8):1491-501. doi: 10.1039/c4mt00112e.

PMID:
24828756
2.

Novel and Versatile Imine-N-Heterocyclic Carbene Half-Sandwich Iridium(III) Complexes as Lysosome-Targeted Anticancer Agents.

Yang Y, Guo L, Tian Z, Gong Y, Zheng H, Zhang S, Xu Z, Ge X, Liu Z.

Inorg Chem. 2018 Sep 4;57(17):11087-11098. doi: 10.1021/acs.inorgchem.8b01656. Epub 2018 Aug 22.

PMID:
30133276
3.

A dual-targeting, p53-independent, apoptosis-inducing platinum(II) anticancer complex, [Pt(BDI(QQ))]Cl.

Suntharalingam K, Wilson JJ, Lin W, Lippard SJ.

Metallomics. 2014 Mar;6(3):437-43. doi: 10.1039/c3mt00364g. Epub 2014 Feb 11.

4.

Organometallic Iridium(III) anticancer complexes with new mechanisms of action: NCI-60 screening, mitochondrial targeting, and apoptosis.

Hearn JM, Romero-Canelón I, Qamar B, Liu Z, Hands-Portman I, Sadler PJ.

ACS Chem Biol. 2013;8(6):1335-43. doi: 10.1021/cb400070a. Epub 2013 Apr 25.

5.

Biological activity of neutral and cationic iridium(III) complexes with κP and κP,κS coordinated Ph₂PCH₂S(O)xPh (x = 0-2) ligands.

Ludwig G, Mijatović S, Ranđelović I, Bulatović M, Miljković D, Maksimović-Ivanić D, Korb M, Lang H, Steinborn D, Kaluđerović GN.

Eur J Med Chem. 2013 Nov;69:216-22. doi: 10.1016/j.ejmech.2013.08.025. Epub 2013 Aug 29.

PMID:
24042044
6.

Mechanism of cellular accumulation of an iridium(III) pentamethylcyclopentadienyl anticancer complex containing a C,N-chelating ligand.

Novohradsky V, Liu Z, Vojtiskova M, Sadler PJ, Brabec V, Kasparkova J.

Metallomics. 2014 Mar;6(3):682-90. doi: 10.1039/c3mt00341h. Epub 2014 Jan 21.

PMID:
24448555
8.

Cyclometalated iridium(III)-guanidinium complexes as mitochondria-targeted anticancer agents.

Song XD, Kong X, He SF, Chen JX, Sun J, Chen BB, Zhao JW, Mao ZW.

Eur J Med Chem. 2017 Sep 29;138:246-254. doi: 10.1016/j.ejmech.2017.06.038. Epub 2017 Jun 23.

PMID:
28668477
9.

Overcoming cisplatin resistance using gold(III) mimics: anticancer activity of novel gold(III) polypyridyl complexes.

Palanichamy K, Sreejayan N, Ontko AC.

J Inorg Biochem. 2012 Jan;106(1):32-42. doi: 10.1016/j.jinorgbio.2011.08.013. Epub 2011 Sep 12.

PMID:
22112837
10.

Cellular response to antitumor cis-Dichlorido platinum(II) complexes of CDK inhibitor Bohemine and its analogues.

Liskova B, Zerzankova L, Novakova O, Kostrhunova H, Travnicek Z, Brabec V.

Chem Res Toxicol. 2012 Feb 20;25(2):500-9. doi: 10.1021/tx200525n. Epub 2012 Feb 1.

PMID:
22250642
11.

Coumarin-appended phosphorescent cyclometalated iridium(iii) complexes as mitochondria-targeted theranostic anticancer agents.

Ye RR, Tan CP, Ji LN, Mao ZW.

Dalton Trans. 2016 Aug 16;45(33):13042-51. doi: 10.1039/c6dt00601a.

PMID:
27139504
12.

Anticancer potential of (pentamethylcyclopentadienyl)chloridoiridium(III) complexes bearing κP and κP,κS-coordinated Ph2 PCH2 CH2 CH2 S(O)x Ph (x=0-2) ligands.

Ludwig G, Ranđelović I, Maksimović-Ivanić D, Mijatović S, Bulatović MZ, Miljković D, Korb M, Lang H, Steinborn D, Kaluđerović GN.

ChemMedChem. 2014 Jul;9(7):1586-93. doi: 10.1002/cmdc.201300479. Epub 2014 Jan 27.

PMID:
24470190
13.

Pharmaco-genomic investigations of organo-iridium anticancer complexes reveal novel mechanism of action.

Hearn JM, Hughes GM, Romero-Canelón I, Munro AF, Rubio-Ruiz B, Liu Z, Carragher NO, Sadler PJ.

Metallomics. 2018 Jan 24;10(1):93-107. doi: 10.1039/c7mt00242d.

PMID:
29131211
14.

Cellular impact and selectivity of half-sandwich organorhodium(III) anticancer complexes and their organoiridium(III) and trichloridorhodium(III) counterparts.

Geldmacher Y, Splith K, Kitanovic I, Alborzinia H, Can S, Rubbiani R, Nazif MA, Wefelmeier P, Prokop A, Ott I, Wölfl S, Neundorf I, Sheldrick WS.

J Biol Inorg Chem. 2012 Apr;17(4):631-46. doi: 10.1007/s00775-012-0883-2. Epub 2012 Feb 23.

PMID:
22358334
15.

Photoinduced anticancer activity studies of iridium(III) complexes targeting mitochondria and tubules.

Zhang WY, Yi QY, Wang YJ, Du F, He M, Tang B, Wan D, Liu YJ, Huang HL.

Eur J Med Chem. 2018 May 10;151:568-584. doi: 10.1016/j.ejmech.2018.04.013. Epub 2018 Apr 7.

PMID:
29656200
16.

Membrane localized iridium(III) complex induces endoplasmic reticulum stress and mitochondria-mediated apoptosis in human cancer cells.

Cao R, Jia J, Ma X, Zhou M, Fei H.

J Med Chem. 2013 May 9;56(9):3636-44. doi: 10.1021/jm4001665. Epub 2013 Apr 25.

PMID:
23594206
17.

Sensitization of p53-mutated epithelial ovarian cancer to CD95-mediated apoptosis is synergistically induced by cisplatin pretreatment.

Bagnoli M, Balladore E, Luison E, Alberti P, Raspagliesi F, Marcomini B, Canevari S, Mezzanzanica D.

Mol Cancer Ther. 2007 Feb;6(2):762-72.

18.

Human bladder cancer cells undergo cisplatin-induced apoptosis that is associated with p53-dependent and p53-independent responses.

Konstantakou EG, Voutsinas GE, Karkoulis PK, Aravantinos G, Margaritis LH, Stravopodis DJ.

Int J Oncol. 2009 Aug;35(2):401-16.

PMID:
19578756
19.

Significant effects of counteranions on the anticancer activity of iridium(iii) complexes.

Zhang H, Guo L, Tian Z, Tian M, Zhang S, Xu Z, Gong P, Zheng X, Zhao J, Liu Z.

Chem Commun (Camb). 2018 Apr 26;54(35):4421-4424. doi: 10.1039/c8cc01326h.

PMID:
29648559
20.

Half-sandwich iridium N-heterocyclic carbene anticancer complexes.

Wang C, Liu J, Tian Z, Tian M, Tian L, Zhao W, Liu Z.

Dalton Trans. 2017 May 30;46(21):6870-6883. doi: 10.1039/c7dt00575j.

PMID:
28405646

Supplemental Content

Support Center